Cardiol Therapeutics Inc. (CRDL) Form 6-K — Nov 12, 2026
Cardiol Therapeutics filed unaudited Q3 2026 financials showing a quarterly net loss of CAD 13.3 million, widened from CAD 10.0 million a year earlier, with nine-month losses of CAD 30.2 million versus CAD 26.6 million in 2025. The loss increase was driven largely by a CAD 3.9 million non-cash charge from the derivative warrant liability; operating losses were roughly flat quarter-over-quarter. The clinical-stage company has no revenue.
Key figures
- Total Debt
- 5282533
- Total Assets
- 32885787
- Cash Position
- 29229802
- Shares outstanding
- 121617823
- Weighted avg shares q3
- 118028542
- Warrant exercise proceeds cad
- 10047603
- Unit financing gross proceeds cad
- 14850001
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.